| Literature DB >> 21946276 |
Tina R White1, Chad M Renzelman, Arthur C Rand, Taha Rezai, Cayla M McEwen, Vladimir M Gelev, Rushia A Turner, Roger G Linington, Siegfried S F Leung, Amit S Kalgutkar, Jonathan N Bauman, Yizhong Zhang, Spiros Liras, David A Price, Alan M Mathiowetz, Matthew P Jacobson, R Scott Lokey.
Abstract
Backbone N-methylation is common among peptide natural products and has a substantial impact on both the physical properties and the conformational states of cyclic peptides. However, the specific impact of N-methylation on passive membrane diffusion in cyclic peptides has not been investigated systematically. Here we report a method for the selective, on-resin N-methylation of cyclic peptides to generate compounds with drug-like membrane permeability and oral bioavailability. The selectivity and degree of N-methylation of the cyclic peptide was dependent on backbone stereochemistry, suggesting that conformation dictates the regiochemistry of the N-methylation reaction. The permeabilities of the N-methyl variants were corroborated by computational studies on a 1,024-member virtual library of N-methyl cyclic peptides. One of the most permeable compounds, a cyclic hexapeptide (molecular mass = 755 Da) with three N-methyl groups, showed an oral bioavailability of 28% in rat.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21946276 PMCID: PMC3210067 DOI: 10.1038/nchembio.664
Source DB: PubMed Journal: Nat Chem Biol ISSN: 1552-4450 Impact factor: 15.040
Figure 1a) Schematic representation of the conformational hypothesis of membrane permeability applied to N-methyl cyclic peptides. b) General strategy for on-resin N-methylation of cyclic peptides to generate scaffolds with improved permeability.
Figure 2a) Diastereomer library screened for N-methylation selectivity. Arrows represent sequences that showed >95% selectivity for a single partially methylated species; all other sequences showed no reaction, permethylation, or mixtures of N-methyl products of varying complexity. Scaffolds 18 and 19 correspond to compounds 2 and 1, respectively. b) Consensus sequences for trimethyl- and tetramethyl-selective compounds.
Figure 3a) Reaction sequence in the on-resin N-methylation of 1 and 2, and the resulting pattern of alkylation to generate 3 and 4, respectively. H/D exchange studies on 1 and 3 (b) along with 2 and 4 (c). Amide N-H resonances were monitored as a function of time after addition of 5% MeOH-d/0.5% HOAc-d.
Figure 4(a) Passive membrane permeabilities of compounds based on diastereomer 1 (white bars), diastereomer 2 (hashed bars), and the orally bioavailable positive control propranolol (grey bar) determined using the parallel artificial membrane permeability assay (PAMPA). %T calculated as the percentage of analyte entering the acceptor compartment after 16 h, where 100% T corresponds to equilibrium between donor and acceptor compartments. (b) Schematic structure of 7, an isomer of 3 with a different pattern of N-methylation, and a stereoview of its predicted membrane-associated conformation. (c) Table showing H-D exchange data for compounds 3 and 7.
Figure 5Predicted free energies of desolvation of all N-methyl variants for scaffolds 1 (a) and 2 (b). Compounds 3 and 4 are indicated with red circles. Compound 7 is indicated with a blue circle. c) Predicted free energies of desolvation of all N-methyl variants for all diastereomers based on the sequence cyclo[D/L-Leu; D/L-Leu; D/L-Leu; D/L-Leu; D/L-Pro-LTyr]. d) Boxplot showing the PAMPA permeabilities (%T) as a function of the number of N-methyl groups for starting materials (0 N-methyls) and products (1–5 N-methyls) derived from the on-resin N-methylation of scaffolds 12, 19, 21, and 23 (Figure 2a) under three different solvent conditions: 1) LiOtBu (THF)/CH3I (THF), 2) LiOtBu (DCM)/CH3I (DCM), 3) LiOtBu (THF)/CH3I (DMSO).
In vitro cell permeability, microsomal stability, and serum stability data for selected cyclic peptides.
| compound | RRCK pH 7.4(× 106cm/s) | HLM Clint (μg/min/mg) | RLM Clint (μg/min/mg) | Human plasma stab ( |
|---|---|---|---|---|
| CSA | 1.1 | 46.8 | 14.1 | > 360 |
| 1.8 | 225 | 243 | > 360 | |
| 4.9 | 110 | 30.4 | > 360 | |
| 3.5 | >320 | 317 | >360 | |
| 0.5 | 109 | 47.1 | >360 | |
| 4.1 | >320 | >491 | >360 | |
| 6.1 | 191 | 62.6 | >360 |
Permeability and microsomal stability data on Leu-to-Ser substitutions in compound 3.
|
| ||||||||
|---|---|---|---|---|---|---|---|---|
| cpd | R1 | R3 | R4 | PAMPA (%T) | RRCK pH 7.4 (× 106cm/s) | HLM Clint (μg/min/mg) | RLM Clint (μg/min/mg) | Human plasma stab ( |
| −OH | < 0.08 | 1.9 | 54 | 98 | > 360 | |||
| −OH | < 0.08 | 1.6 | 85 | 53 | > 360 | |||
| −OH | < 0.08 | 0.76 | 271 | 507 | >360 | |||
Rat Pharmacokinetics for compound 3 and CSA.
|
| ||||||
|---|---|---|---|---|---|---|
| i.v. administration | p.o. administration | |||||
|
| ||||||
| compound | CL (mL/min/kg) | Vdss (L/kg) | AUC (ng.h/mL) | Cmax (ng/mL) | ||
| 4.5 | 1.1 | 2.8 | 10.5 | 852 | 28% | |
| 3.5 | 1.2 | 6.0 | 13.8 | 1440 | 29% | |
CL and Vdss, AUC, and %F were obtained from ref.[28]; t1/2 and Cmax values were obtained from ref. [29].